中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
119-120
,共2页
唐捷%龙云%苏强%夏小燕%张惠
唐捷%龍雲%囌彊%夏小燕%張惠
당첩%룡운%소강%하소연%장혜
幽门螺杆菌%根除率%疗效分析
幽門螺桿菌%根除率%療效分析
유문라간균%근제솔%료효분석
Helicobacter Pylori%eradication rate%efficacy analysis
目的:对4种根除幽门螺杆菌( HP )感染的治疗方案进行疗效评价。方法选择2014年就诊的经13C-尿素呼气试验(13C-UBT)或经胃黏膜活检快速尿素酶试验( RUT )确定为HP感染的患者240例,随机分为A、B、C、D组,每组60例,A组给予雷贝拉唑+阿莫西林+克拉霉素治疗;B组给予雷贝拉唑+阿莫西林+左氧氟沙星治疗;C组给予雷贝拉唑+枸橼酸铋钾+阿莫西林+呋喃唑酮治疗;D组给予给予雷贝拉唑+阿莫西林+克拉霉素+双歧杆菌三联活菌肠溶胶囊治疗;疗程均为14 d。结果 A,B,C,D组的HP的根除率分别为61.67%,63.33%,93.33%和91.67%,A组、B组疗效无显著性差异( P>0.05),C组、D组疗效无显著性差异( P>0.05),但A组、B组与C组、D组疗效有显著性差异( P<0.05)。结论传统的三联疗法以及含左氧氟沙星的三联疗法的HP根除率不理想,加用标准剂量的铋制剂或微生态制剂可显著提高HP根除率,是治疗HP感染的新途径。
目的:對4種根除幽門螺桿菌( HP )感染的治療方案進行療效評價。方法選擇2014年就診的經13C-尿素呼氣試驗(13C-UBT)或經胃黏膜活檢快速尿素酶試驗( RUT )確定為HP感染的患者240例,隨機分為A、B、C、D組,每組60例,A組給予雷貝拉唑+阿莫西林+剋拉黴素治療;B組給予雷貝拉唑+阿莫西林+左氧氟沙星治療;C組給予雷貝拉唑+枸櫞痠鉍鉀+阿莫西林+呋喃唑酮治療;D組給予給予雷貝拉唑+阿莫西林+剋拉黴素+雙歧桿菌三聯活菌腸溶膠囊治療;療程均為14 d。結果 A,B,C,D組的HP的根除率分彆為61.67%,63.33%,93.33%和91.67%,A組、B組療效無顯著性差異( P>0.05),C組、D組療效無顯著性差異( P>0.05),但A組、B組與C組、D組療效有顯著性差異( P<0.05)。結論傳統的三聯療法以及含左氧氟沙星的三聯療法的HP根除率不理想,加用標準劑量的鉍製劑或微生態製劑可顯著提高HP根除率,是治療HP感染的新途徑。
목적:대4충근제유문라간균( HP )감염적치료방안진행료효평개。방법선택2014년취진적경13C-뇨소호기시험(13C-UBT)혹경위점막활검쾌속뇨소매시험( RUT )학정위HP감염적환자240례,수궤분위A、B、C、D조,매조60례,A조급여뢰패랍서+아막서림+극랍매소치료;B조급여뢰패랍서+아막서림+좌양불사성치료;C조급여뢰패랍서+구연산필갑+아막서림+부남서동치료;D조급여급여뢰패랍서+아막서림+극랍매소+쌍기간균삼련활균장용효낭치료;료정균위14 d。결과 A,B,C,D조적HP적근제솔분별위61.67%,63.33%,93.33%화91.67%,A조、B조료효무현저성차이( P>0.05),C조、D조료효무현저성차이( P>0.05),단A조、B조여C조、D조료효유현저성차이( P<0.05)。결론전통적삼련요법이급함좌양불사성적삼련요법적HP근제솔불이상,가용표준제량적필제제혹미생태제제가현저제고HP근제솔,시치료HP감염적신도경。
Objective To evaluate the efficacy of four kinds of treatment Programs for the eradication of Helicobacter Pylori infection. Methods 240 cases of Patients identified with H. Pylori infection by the 13C-urea breath test ( 13C-UBT ) or by mucosal bioPsy raPid urease test ( RUT ) were randomly divided into 4 grouPs of A, B, C, D, 60 cases in each grouP. GrouP A were given rabePrazole+amoxicillin+clarithromycin; grouP B received rabePrazole+amoxicillin+levofloxacin; grouP C were given rabePrazole+bismuth Potassium citrate+amoxicillin+furazolidone; grouP D received rabePrazole+amoxicillin Plus clarithromycin triPle viable Bifidobacterium enteric-coated caPsules; the treatment course of all grouPs were 14 d. Results The HP eradication rates of the four grouPs were 61. 67%, 63. 33%, 93. 33%, 91. 67% resPectively;the efficacy of grouP A and grouP B had no significant difference ( P > 0. 05 ) , and the efficacy of grouP C and grouP D had no significant difference ( P > 0. 05 ) , but there was a significant difference between grouP A, B and grouP C, D ( P < 0. 05 ) . Conclusion The HP eradication rate of the traditional triPle theraPy and levofloxacin triPle theraPy is not ide-al. Adding a standard dose of bismuth PreParations or Probiotics can significantly imProve the HP eradication rate, and is a new way to treat HP infection.